Article
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
PloS one - 1 Jan 2020
DeLeon Thomas T, Almquist Daniel R, Kipp Benjamin R, Langlais Blake T, Mangold Aaron, Winters Jennifer L, Kosiorek Heidi E, Joseph Richard W, Dronca Roxana S, Block Matthew S, McWilliams Robert R, Kottschade Lisa A, Rumilla Kandelaria M, Voss Jesse S, Seetharam Mahesh, Sekulic Aleksandar, Markovic Svetomir N, Bryce Alan H
Abstract excerpt
BACKGROUND: CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of patients treated with checkpoint inhibitors. METHODS: All patients with cutaneous melanoma or melanoma of unknown primary who received checkpoint inhibitor therapy and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.